US Regulator's Scrutiny On Indian Drug Makers To Remain Intense: Crisil
Business | Press Trust of India | Wednesday August 10, 2016
Regulatory scrutiny of the US Food and Drug Administration (FDA) for domestic pharmaceutical facilities is expected to remain intense over the medium term, rating agency Crisil said on Wednesday.
Advent, Baxter Set To Submit Bids For India's Gland Pharma: Report
Business | Thomson Reuters | Friday April 15, 2016
Global buyout firm Advent International and U.S.-based Baxter International are among suitors preparing to submit separate bids to buy unlisted Indian drugmaker Gland Pharma Ltd, three people with direct knowledge of the matter told Reuters.
Two Indian Generics Makers End Battle to Copy Drugs Amid Patent Debate
Business | Thomson Reuters | Tuesday April 12, 2016
Two Indian drug makers said they had given up a battle to copy drugs developed by Bristol Myers Squibb and AstraZeneca, blaming a lack of government support for cheap generics and pressure from Big Pharma.
More Inspections Due to Rising Drug Imports From India: USFDA
Business | Press Trust of India | Sunday February 28, 2016
The USFDA had taken action against companies like Sun Pharma and Ranbaxy.
Dr Reddy's, BioMarin Settle Patent Litigation on Kuvan Tablets
Business | Press Trust of India | Monday September 21, 2015
According to a statement issued by BioMarin, the US drugmaker said it will grant Dr Reddy's a non-exclusive licence to its patents on Kuvan (sapropterin dihydrochloride) allowing the Indian drug maker to market a generic version of Kuvan 100mg tablets in the US at a later stage, which is expected to be more than five years from now.
Dr Reddy's Lab to Enter Japanese Market Through a Partner
Business | Tuesday May 12, 2015
The Indian drug maker and Fujifilm Corporation of Japan had earlier entered into an MoU for an exclusive partnership in the generic drugs business for the Japanese market and to establish a joint venture in the island nation.
FDA Says Indian Drug Firms Not Singled Out for Inspections
Business | Wednesday March 18, 2015
With many major Indian drug makers coming under more intense scrutiny from it, the US Food and Drug Administration (FDA) on Wednesday said it has not singled out domestic manufacturers and that the increased number of inspections here is a reflection of increasing size of the country's pharmaceutical industry.
Indian Drug Makers to Pay Higher Facility Fees on US Hike
Business | Sunday August 3, 2014
Drug makers from India, the biggest source of medicines to the US, may soon have to cough up 12-15 per cent more in annual facility fees as the Food and Drug Administration (FDA) has announced new rates.
Daiichi has failed to run Ranbaxy successfully: Malvinder Singh
Business | Monday April 7, 2014
Mumbai-based Sun Pharma has said it will acquire troubled Indian drug maker Ranbaxy in a $4-billion (Rs. 24,000 crore at 60 rupees to the US dollar) deal.
Sun Pharma to acquire Ranbaxy in $4 billion all-stock deal
India News | NDTV.com | Monday April 7, 2014
Mumbai-based Sun Pharma will acquire troubled Indian drug maker Ranbaxy in a US$ 4 billion all-stock transaction, the company said in a statement on Monday.
India pharma companies should follow strict regulations: FDA
Business | Friday August 30, 2013
In its latest action against Indian drug makers, the US health regulator FDA had red- flagged "significant deviations" from good manufacturing practices by two Indian pharmaceutical companies: Hyderabad-based Posh Chemicals and Himachal Pradesh-based Sentiss Pharma (formerly Promed Exports).
Indian drug makers face higher costs for sale in US
Business | Sunday August 11, 2013
Many Indian drug makers will soon have to bear higher costs for sale of products in American markets, as the US Food and Drug Administration (FDA) is hiking the fees for generic drug makers by up to 48 per cent from October.
Wockhardt plunges after FDA warning, downgrade
Business | Wednesday July 24, 2013
Brokerage Macquarie downgraded on Wednesday shares in Indian drug maker Wockhardt on concerns that an import ban imposed by the United States over quality issues would last longer than expected, sending the stock down 20 per cent.
Cipla to buy 51 per cent stake in South Africa's Cipla Medpro
Business | Thursday November 22, 2012
Indian drugs maker Cipla Limited has offered to buy a about a 51 percent stake in South Africa's Cipla Medpro, to strengthen its position in the fast-growing African drugs market.
Sun Pharma up on US court's diabetes ruling
Business | Wednesday April 18, 2012
Sun Pharmaceutical Industries rose 2.4 per cent after the U.S. Supreme Court allowed the Indian drug maker to sue a brand name rival
Indian drug makers gear up to fight swine flu
Apr 28, 2009
India, the ideal prescription for pharma majors
Mar 30, 2009
Pharma too not immune to meltdown
Jan 1, 2009
Indian Pharma to prune R&D budget
Nov 5, 2008
Pharma cos eye buyouts in US, Europe
Sep 1, 2008
Japan: The new medicine hub
Aug 1, 2008
Paswan talks tough on drug pricing
Nov 14, 2006
US Regulator's Scrutiny On Indian Drug Makers To Remain Intense: Crisil
Business | Press Trust of India | Wednesday August 10, 2016
Regulatory scrutiny of the US Food and Drug Administration (FDA) for domestic pharmaceutical facilities is expected to remain intense over the medium term, rating agency Crisil said on Wednesday.
Advent, Baxter Set To Submit Bids For India's Gland Pharma: Report
Business | Thomson Reuters | Friday April 15, 2016
Global buyout firm Advent International and U.S.-based Baxter International are among suitors preparing to submit separate bids to buy unlisted Indian drugmaker Gland Pharma Ltd, three people with direct knowledge of the matter told Reuters.
Two Indian Generics Makers End Battle to Copy Drugs Amid Patent Debate
Business | Thomson Reuters | Tuesday April 12, 2016
Two Indian drug makers said they had given up a battle to copy drugs developed by Bristol Myers Squibb and AstraZeneca, blaming a lack of government support for cheap generics and pressure from Big Pharma.
More Inspections Due to Rising Drug Imports From India: USFDA
Business | Press Trust of India | Sunday February 28, 2016
The USFDA had taken action against companies like Sun Pharma and Ranbaxy.
Dr Reddy's, BioMarin Settle Patent Litigation on Kuvan Tablets
Business | Press Trust of India | Monday September 21, 2015
According to a statement issued by BioMarin, the US drugmaker said it will grant Dr Reddy's a non-exclusive licence to its patents on Kuvan (sapropterin dihydrochloride) allowing the Indian drug maker to market a generic version of Kuvan 100mg tablets in the US at a later stage, which is expected to be more than five years from now.
Dr Reddy's Lab to Enter Japanese Market Through a Partner
Business | Tuesday May 12, 2015
The Indian drug maker and Fujifilm Corporation of Japan had earlier entered into an MoU for an exclusive partnership in the generic drugs business for the Japanese market and to establish a joint venture in the island nation.
FDA Says Indian Drug Firms Not Singled Out for Inspections
Business | Wednesday March 18, 2015
With many major Indian drug makers coming under more intense scrutiny from it, the US Food and Drug Administration (FDA) on Wednesday said it has not singled out domestic manufacturers and that the increased number of inspections here is a reflection of increasing size of the country's pharmaceutical industry.
Indian Drug Makers to Pay Higher Facility Fees on US Hike
Business | Sunday August 3, 2014
Drug makers from India, the biggest source of medicines to the US, may soon have to cough up 12-15 per cent more in annual facility fees as the Food and Drug Administration (FDA) has announced new rates.
Daiichi has failed to run Ranbaxy successfully: Malvinder Singh
Business | Monday April 7, 2014
Mumbai-based Sun Pharma has said it will acquire troubled Indian drug maker Ranbaxy in a $4-billion (Rs. 24,000 crore at 60 rupees to the US dollar) deal.
Sun Pharma to acquire Ranbaxy in $4 billion all-stock deal
India News | NDTV.com | Monday April 7, 2014
Mumbai-based Sun Pharma will acquire troubled Indian drug maker Ranbaxy in a US$ 4 billion all-stock transaction, the company said in a statement on Monday.
India pharma companies should follow strict regulations: FDA
Business | Friday August 30, 2013
In its latest action against Indian drug makers, the US health regulator FDA had red- flagged "significant deviations" from good manufacturing practices by two Indian pharmaceutical companies: Hyderabad-based Posh Chemicals and Himachal Pradesh-based Sentiss Pharma (formerly Promed Exports).
Indian drug makers face higher costs for sale in US
Business | Sunday August 11, 2013
Many Indian drug makers will soon have to bear higher costs for sale of products in American markets, as the US Food and Drug Administration (FDA) is hiking the fees for generic drug makers by up to 48 per cent from October.
Wockhardt plunges after FDA warning, downgrade
Business | Wednesday July 24, 2013
Brokerage Macquarie downgraded on Wednesday shares in Indian drug maker Wockhardt on concerns that an import ban imposed by the United States over quality issues would last longer than expected, sending the stock down 20 per cent.
Cipla to buy 51 per cent stake in South Africa's Cipla Medpro
Business | Thursday November 22, 2012
Indian drugs maker Cipla Limited has offered to buy a about a 51 percent stake in South Africa's Cipla Medpro, to strengthen its position in the fast-growing African drugs market.
Sun Pharma up on US court's diabetes ruling
Business | Wednesday April 18, 2012
Sun Pharmaceutical Industries rose 2.4 per cent after the U.S. Supreme Court allowed the Indian drug maker to sue a brand name rival
Indian drug makers gear up to fight swine flu
Apr 28, 2009
India, the ideal prescription for pharma majors
Mar 30, 2009
Pharma too not immune to meltdown
Jan 1, 2009
Indian Pharma to prune R&D budget
Nov 5, 2008
Pharma cos eye buyouts in US, Europe
Sep 1, 2008
Japan: The new medicine hub
Aug 1, 2008
Paswan talks tough on drug pricing
Nov 14, 2006
................................ Advertisement ................................
................................ Advertisement ................................
